Quick Answer
Burning Rock Biotech Ltd reported R&D Expense of $232.29 million for fiscal year 2024.
Burning Rock Biotech Ltd R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $232.29M | -33.1% |
| 2023 | $347.02M | -17.7% |
| 2022 | $421.87M | +14.7% |
| 2021 | $367.86M | +39.4% |
| 2020 | $263.94M | +68.2% |
| 2019 | $156.94M | +49.0% |
| 2018 | $105.30M | — |
- Burning Rock Biotech Ltd showed a decrease of -33.1% in R&D Expense compared to the prior fiscal year.
- Over the 2018–2024 period, Burning Rock Biotech Ltd’s r&d expense has grown by 120.6% (from $105.30 million to $232.29 million).
- The most recent figure is from Burning Rock Biotech Ltd’s fiscal year 2024 report (Form 20-F), filed with the SEC on April 29, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: